{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-110177","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.943583+00:00","generated_at":"2026-05-31T00:46:14.935353+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kezar halts lupus trial after 4 deaths; IDMC recommends stop","bullets":["Voluntary cessation of enrollment and dosing in PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis.","IDMC recommendation after review of 4 Grade 5 (fatal) serious adverse events in Philippines and Argentina.","Three fatalities showed common symptom pattern and proximity to dosing; additional non-fatal SAEs with similar pattern.","Kezar remains blinded to treatment arms; no prior deaths or serious opportunistic infections in earlier trials.","PORTOLA trial in autoimmune hepatitis continues enrollment; no Grade 4 or 5 SAEs observed there to date."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-110177","json":"https://secwatch.observer/filing/0000950170-24-110177.json","markdown":"https://secwatch.observer/filing/0000950170-24-110177.md","text":"https://secwatch.observer/filing/0000950170-24-110177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024110177/0000950170-24-110177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024110177/kzr-20240930.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:46:14.935353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}